Showing 551-560 of 1100 results for "".
- From AAD: What's New in Acne and Rosacea?https://practicaldermatology.com/news/from-aad-whats-new-in-acne-and-rosacea/2471565/Dermatologists gathered for the Acne and Rosacea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD,
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Analysis: Hydrating Ointment Rivals Steroid Cream in Eczema Severity Reductionhttps://practicaldermatology.com/news/analysis-hydrating-ointment-rivals-steroid-cream-in-eczema-severity-reduction/2471140/New research suggests a petrolatum and panthenol-based ointment (HO) was as effective as 0.1% triamcinolone acetonide in urea cream (TAU) in reducing the severity of mild-to-moderate chronic hand eczema (CHE). Researchers includ
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://practicaldermatology.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- Heart Transplant Patients Show Increased Skin Cancer Incidence: Meta-Analysishttps://practicaldermatology.com/news/heart-transplant-patients-show-increased-skin-cancer-incidence-meta-analysis/2470902/Heart transplant (HTx) recipients face a 16% overall risk of developing skin cancer, with squamous and basal cell carcinomas being the most common forms, a new meta-analysis indicated. "Studies have shown that patients who undergo HTx are at an increased risk for developing skin cancer," t